Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort.
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort.
复制标题
参加记忆诊所的非痴呆受试者中的认知和成像标记：纪念品队列的研究设计和基线发现。
DOI：
10.1186/s13195-017-0288-0
复制
发表时间：
2017-08-29
期刊：
影响因子：
--
通讯作者：
MEMENTO cohort Study Group
中科院分区：
文献类型：
--
作者：
Dufouil C;Dubois B;Vellas B;Pasquier F;Blanc F;Hugon J;Hanon O;Dartigues JF;Harston S;Gabelle A;Ceccaldi M;Beauchet O;Krolak-Salmon P;David R;Rouaud O;Godefroy O;Belin C;Rouch I;Auguste N;Wallon D;Benetos A;Pariente J;Paccalin M;Moreaud O;Hommet C;Sellal F;Boutoleau-Bretonniére C;Jalenques I;Gentric A;Vandel P;Azouani C;Fillon L;Fischer C;Savarieau H;Operto G;Bertin H;Chupin M;Bouteloup V;Habert MO;Mangin JF;Chêne G;MEMENTO cohort Study Group
阿尔茨海默病及相关疾病 (ADRD) 的自然史和疾病机制仍知之甚少。很少有资源可用于根据需要尽早对患者进行检查，并使用将标准化、重复的临床研究和尖端生物标志物测量相结合的综合方法。在全国性的法国 MMENTO 队列研究中，参与者在记忆诊所招募，并筛查孤立的主观认知障碍 (SCC) 或轻度认知障碍 (MCI；定义为测试表现低于年龄、性别和教育水平标准 1.5 个标准差)，但没有痴呆（临床痴呆评级 [CDR] <1）。基线数据收集包括神经学和体格检查以及广泛的神经心理学测试。要纳入 MMENTO 队列，参与者必须同意接受脑部磁共振成像 (MRI) 和血液采样。脑 18F-氟脱氧葡萄糖正发射断层扫描和腰椎穿刺是可选的。脑 MRI 的自动分析包括对全脑、海马和白质病变体积的评估。 2011 年 4 月至 2014 年 6 月期间招募的 2323 名参与者平均年龄为 71 岁（SD 8.7），其中 62% 为女性。 40% 的参与者的 CDR 为 0，30% 的参与者携带至少一种载脂蛋白 E ε4 等位基因。我们观察到，超过一半 (52%) 的参与者患有遗忘性轻度认知障碍（17% 单域 aMCI），32% 患有非遗忘性轻度认知障碍（16.9% 单域 naMCI），16% 患有孤立性 SCC。对神经影像标记物与认知类别关联的多变量分析表明，aMCI 参与者的影像生物标记物水平比其他人差，而 naMCI 参与者的标记物水平介于 SCC 和 aMCI 之间。 aMCI 参与者的白质病变负担往往更大。独立于 CDR，所有神经影像学和神经心理学标志物都随着年龄的增长而恶化，而不同性别的差异并不一致。 MMENTO 是一个拥有广泛临床、神经心理学和神经影像学数据的大型队列，代表了一个研究一大群具有不同 MCI 亚型（遗忘或非遗忘）或孤立性 SCC 参与者的 ADRD 自然史的平台。临床试验.gov，NCT01926249。注册于 2013 年 8 月 16 日。本文的在线版本 (doi:10.1186/s13195-017-0288-0) 包含补充材料，可供授权用户使用。
The natural history and disease mechanisms of Alzheimer’s disease and related disorders (ADRD) are still poorly understood. Very few resources are available to scrutinise patients as early as needed and to use integrative approaches combining standardised, repeated clinical investigations and cutting-edge biomarker measurements. In the nationwide French MEMENTO cohort study, participants were recruited in memory clinics and screened for either isolated subjective cognitive complaints (SCCs) or mild cognitive impairment (MCI; defined as test performance 1.5 SD below age, sex and education-level norms) while not demented (Clinical Dementia Rating [CDR] <1). Baseline data collection included neurological and physical examinations as well as extensive neuropsychological testing. To be included in the MEMENTO cohort, participants had to agree to undergo both brain magnetic resonance imaging (MRI) and blood sampling. Cerebral 18F-fluorodeoxyglucose positon emission tomography and lumbar puncture were optional. Automated analyses of cerebral MRI included assessments of volumes of whole-brain, hippocampal and white matter lesions. The 2323 participants, recruited from April 2011 to June 2014, were aged 71 years, on average (SD 8.7), and 62% were women. CDR was 0 in 40% of participants, and 30% carried at least one apolipoprotein E ε4 allele. We observed that more than half (52%) of participants had amnestic mild cognitive impairment (17% single-domain aMCI), 32% had non-amnestic mild cognitive impairment (16.9% single-domain naMCI) and 16% had isolated SCCs. Multivariable analyses of neuroimaging markers associations with cognitive categories showed that participants with aMCI had worse levels of imaging biomarkers than the others, whereas participants with naMCI had markers at intermediate levels between SCC and aMCI. The burden of white matter lesions tended to be larger in participants with aMCI. Independently of CDR, all neuroimaging and neuropsychological markers worsened with age, whereas differences were not consistent according to sex. MEMENTO is a large cohort with extensive clinical, neuropsychological and neuroimaging data and represents a platform for studying the natural history of ADRD in a large group of participants with different subtypes of MCI (amnestic or not amnestic) or isolated SCCs. Clinicaltrials.gov, NCT01926249. Registered on 16 August 2013. The online version of this article (doi:10.1186/s13195-017-0288-0) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
7
作者：
de Medeiros K;Robert P;Gauthier S;Stella F;Politis A;Leoutsakos J;Taragano F;Kremer J;Brugnolo A;Porsteinsson AP;Geda YE;Brodaty H;Gazdag G;Cummings J;Lyketsos C
通讯作者：
Lyketsos C
影响因子：
--
作者：
Dickerson, Bradford C.;Sperling, Reisa A.;Blacker, Deborah
通讯作者：
Blacker, Deborah
影响因子：
--
作者：
BENTON, AL;VARNEY, NR;HAMSHER, KD
通讯作者：
HAMSHER, KD
影响因子：
5.7
作者：
Guevara, P.;Duclap, D.;Mangin, J. -F.
通讯作者：
Mangin, J. -F.
阿尔茨海默病发病机制的进展：淀粉样蛋白级联假说的重新评估
影响因子：
12.6
作者：
Dong S;Duan Y;Hu Y;Zhao Z
通讯作者：
Zhao Z